Mark A. Ashwell

ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity

Neru Munshi, Sébastien Jeay, Youzhi Li et al. · Molecular Cancer Therapeutics · 2010 · 320 citations

Medicine, Oncology, Pharmacology +17

Discovery of a Novel Mode of Protein Kinase Inhibition Characterized by the Mechanism of Inhibition of Human Mesenchymal-epithelial Transition Factor (c-Met) Protein Autophosphorylation by ARQ 197

Sudharshan Eathiraj, Rocio Palma, Erika Volckova et al. · Journal of Biological Chemistry · 2011 · 139 citations · Full text

Medicine, Oncology, Pharmacology +16

Identification of pathway-selective estrogen receptor ligands that inhibit NF-κB transcriptional activity

Christopher C. Chadwick, Susan Chippari, Edward Matelan et al. · Proceedings of the National Academy of Sciences · 2005 · 135 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Discovery and Optimization of a Series of 3-(3-Phenyl-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-2-yl)pyridin-2-amines: Orally Bioavailable, Selective, and Potent ATP-Independent Akt Inhibitors

Mark A. Ashwell, Jean‐Marc Lapierre, Christopher J. Brassard et al. · Journal of Medicinal Chemistry · 2012 · 100 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Synthesis and Activity of Substituted 4-(Indazol-3-yl)phenols as Pathway-Selective Estrogen Receptor Ligands Useful in the Treatment of Rheumatoid Arthritis

Robert J. Steffan, Edward Matelan, Mark A. Ashwell et al. · Journal of Medicinal Chemistry · 2004 · 70 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17